Scott N. Holden - Concepedia

Author

Scott N. Holden

Also Known As

S Holden, S N Holden, S. Holden, S. N. Holden, S.N. Holden, SCOTT N. HOLDEN, Scott Holden, Scott N Holden, Scott N. Holden, Stuart Holden

Publications

4.7K

Citations

H-Index

Concepts

All Affiliations

University of Colorado Denver University of Colorado Cancer Center University of Colorado Health Sarah Cannon University of Colorado Boulder

About

Scott N. Holden is an author at University of Colorado Denver specializing in medicine, oncology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	16	884
2	Health Sciences	2	2	38
3	Natural Sciences	1	1	17
4	Public Health	1	1	41
5	Biochemistry	1	1	17

Scott N. Holden

Publications

Citations

H-Index

Page 1

	Year	Citations
Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer Ian E. Krop, Muralidhar Beeram, Shanu Modi, Journal of Clinical Oncology	2010	590
Impact of Vascular Endothelial Growth Factor-A Expression, Thrombospondin-2 Expression, and Microvessel Density on the Treatment Effect of Bevacizumab in Metastatic Colorectal Cancer Adrian M. Jubb, Herbert I. Hurwitz, Wei Bai, Journal of Clinical Oncology	2005	389
Association of k-ras, b-raf, and p53 Status With the Treatment Effect of Bevacizumab William L. Ince, Adrian M. Jubb, Scott N. Holden, JNCI Journal of the National Cancer Institute	2005	322
Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors Scott N. Holden, Sabine Eckhardt, R. Basser, Annals of Oncology MedicinePharmacologyPathologyMalignant TumorsAnti-cancer Agent	2005	306
Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer Sandhya Girish, Manish Gupta, Bei Wang, Cancer Chemotherapy and Pharmacology	2012	261
Prevalence of Acid-Reducing Agents (ARA) in Cancer Populations and ARA Drug–Drug Interaction Potential for Molecular Targeted Agents in Clinical Development Gillian S. Smelick, Timothy P. Heffron, Laura Chu, Molecular Pharmaceutics	2013	185
Assessment of the biological and pharmacological effects of the ανβ3 and ανβ5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors Seetharaman Hariharan, Daniel L. Gustafson, Scott N. Holden, Annals of Oncology Molecular PharmacologyOncologyChemoprevention StrategyMedicineReceptor Antagonist	2007	122
A phase 1 study of weekly dosing of trastuzumab emtansine (T‐DM1) in patients with advanced human epidermal growth factor 2–positive breast cancer Muralidhar Beeram, Ian E. Krop, Howard A. Burris, Cancer	2012	102
A Phase I Biological and Pharmacologic Study of the Heparanase Inhibitor PI-88 in Patients with Advanced Solid Tumors M. Basche, Daniel L. Gustafson, Scott N. Holden, Clinical Cancer Research	2006	95
Arterial thromboembolic events (ATEs) in a pooled analysis of 5 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy Jamey Skillings, D. H. Johnson, Kathy D. Miller, Journal of Clinical Oncology	2005	94

Page 1